<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936025</url>
  </required_header>
  <id_info>
    <org_study_id>00/0648-DXM2</org_study_id>
    <nct_id>NCT01936025</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test</brief_title>
  <acronym>DXM2</acronym>
  <official_title>A Phase IIa, Dose-finding, Double-blind, Placebo-controlled, Double-dummy, Randomized, Eightfold Cross-over Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut f端r Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Profil Institut f端r Stoffwechselforschung GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study has a randomized, double-blind, placebo-controlled, double dummy and eight-way
      cross-over design. Males with T2DM on a stable metformin monotherapy will be screened for
      participation in the study. Eligible subjects will be randomized to receive DXM 30 mg, DXM 60
      mg, DXM 90 mg alone or in combination with sitagliptin 100 mg, sitagliptin 100 mg alone, or
      placebo (for DXM and sitagliptin) on in total eight treatment days. An OGTT will be started 1
      hour after study drug administration and blood glucose will be measured over the next 4
      hours. There will be a 3 to 14-day washout period between doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is performed to determine the optimal dose of DXM that, compared to placebo,
      decreases glucose excursions following an OGTT. Doses of 30 mg, 60 mg and 90 mg DXM were
      chosen. Since DXM 60 mg was effective in the previous study in increasing insulin secretion,
      this dose will be kept. A lower dose (30 mg) will be given to see whether effects on insulin
      secretion are present also at lower doses and then translate into a BG lowering action. A
      higher dose (90 mg) will be added to see whether this way an effect on glucose excursion
      reduction occurs following an OGTT, (like previously demonstrated with 270 mg DXM) that can
      be related to an increase of insulin secretion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>lowest dose of DXM</measure>
    <time_frame>up to 4 hours after study drug administration</time_frame>
    <description>To find the lowest dose of DXM that, compared to placebo, exerts BG lowering effects related to an OGTT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>additive BG lowering effects</measure>
    <time_frame>up to 4 hours after study drug administration</time_frame>
    <description>To demonstrate whether the administration of DXM on top of sitagliptin exerts additive BG lowering effects related to an OGTT as compared to sitagliptin alone and DXM alone</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo dextromethorphan + sitagliptin 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan 30 mg + sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan 30 mg + sitagliptin 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan 60 mg + sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan 60 mg + sitagliptin 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan 90 mg + sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan 90 mg + sitagliptin 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan 30 mg + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan 30 mg + placebo (sitagliptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan 60 mg + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan 60 mg + placebo (sitagliptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextromethorphan 90 mg + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dextromethorphan 90 mg + placebo (sitagliptin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (dextromethorphan)+ placebo (sitagliptin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <arm_group_label>Dextromethorphan 30 mg + sitagliptin</arm_group_label>
    <arm_group_label>Dextromethorphan 60 mg + sitagliptin</arm_group_label>
    <arm_group_label>Dextromethorphan 90 mg + sitagliptin</arm_group_label>
    <arm_group_label>Dextromethorphan 30 mg + placebo</arm_group_label>
    <arm_group_label>Dextromethorphan 60 mg + placebo</arm_group_label>
    <arm_group_label>Dextromethorphan 90 mg + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_label>Dextromethorphan 30 mg + sitagliptin</arm_group_label>
    <arm_group_label>Dextromethorphan 60 mg + sitagliptin</arm_group_label>
    <arm_group_label>Dextromethorphan 90 mg + sitagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated written informed consent obtained before any study-related activities

          2. Male subjects with a diagnosis of type 2 diabetes mellitus according to ADA criteria
             at least 4 months prior to screening

          3. Medical history without major pathology (with the exception of type 2 diabetes)

          4. On a stable regimen of metformin monotherapy for at least 3 months

          5. Aged between 45 and 70 years of age, both inclusive

          6. Body mass index (BMI) between 25 and 35kg/m2, both inclusive

        Exclusion Criteria:

          1. Subjects with type 1 diabetes, MODY or secondary forms of diabetes such as due to
             pancreatitis

          2. History of pancreatitis

          3. Current or previous treatment with insulin therapy

          4. Treatment with any hypoglycemic medication other than metformin within the three
             months prior to screening

          5. Mean QTc&gt; 450 msec
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alin Stirban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut f端r Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institut f端r Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2013</study_first_submitted>
  <study_first_submitted_qc>September 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

